0000950103-21-009692.txt : 20210629
0000950103-21-009692.hdr.sgml : 20210629
20210629203111
ACCESSION NUMBER: 0000950103-21-009692
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210625
FILED AS OF DATE: 20210629
DATE AS OF CHANGE: 20210629
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RIGGS RORY B
CENTRAL INDEX KEY: 0001016835
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39329
FILM NUMBER: 211059929
MAIL ADDRESS:
STREET 1: 65 RAILROAD AVE
CITY: RIDGEFIELD
STATE: NJ
ZIP: 07657
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Royalty Pharma plc
CENTRAL INDEX KEY: 0001802768
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 883-0200
MAIL ADDRESS:
STREET 1: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
dp153575_4-riggs.xml
FORM 4
X0306
4
2021-06-25
0
0001802768
Royalty Pharma plc
RPRX
0001016835
RIGGS RORY B
C/O ROYALTY PHARMA PLC
110 E. 59TH STREET
NEW YORK
NY
10022
1
0
0
0
Class A Ordinary Shares
2021-06-25
4
S
0
179100
42.8057
D
933910
I
By New Ventures Select
Class A Ordinary Shares
2021-06-25
4
S
0
487364
42.6940
D
4099706
I
By New Ventures I LLC
Class A Ordinary Shares
2021-06-28
4
S
0
167448
42.1102
D
3932258
I
By New Ventures I LLC
Class A Ordinary Shares
2021-06-29
4
S
0
1200
42.0073
D
3931058
I
By New Ventures I LLC
Class A Ordinary Shares
2021-06-29
4
S
0
479800
41.2556
D
3451258
I
By New Ventures I LLC
Class A Ordinary Shares
679760
D
Class A Ordinary Shares
2081540
I
By New Ventures III LLC
Class A Ordinary Shares
15000
I
By Spouse
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.44 to $43.29 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $43.04 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.90 to $42.79 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jason Mehar, as Attorney-in-Fact for Rory B. Riggs
2021-06-29